Skip to main content

Table 1 Clinicopathological and molecular characteristics of study patients

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Category

Group A

Group B

Group C

No. Patient

34

35

22

Age: median (range)

67.3 (43–85)

69.9 (45–92)

67.1 (55–81)

Gender: female N (%)

22 (64.7%)

17 (48.6%)

10 (45.5%)

Race/ethnicity: N (%)

Non-Hispanic White

16 (47.1%)

32 (91.4%)

17 (77.3%)

Hispanic

1 (2.9%)

1 (2.9%)

4 (18.2%)

Asian

17 (50.0%)

2 (5.7%)

1 (4.5%)

Histology: N (%)

LUAD

33 (97.1%)

25 (74.4%)

14 (63.6%)

LUSC

1 (2.9%)

10 (28.5%)

4 (18.2%)

NSCLC-NOS

0 (0%)

0 (0%)

4 (18.2%)

Driver oncogene mutations:

34 (100%)

0 (0%)

7 (31.8%)

EGFR mutations

24 (70.6%)

0 (0%)

3 (13.6%)

ALK fusions

3 (8.8%)

0 (0%)

2 (9.1%)

HER2 alterations

3 (8.8%)

0 (0%)

1 (4.5%)

MET alterations

3 (8.8%)

0 (0%)

1 (4.5%)

RET fusions

1 (2.9%)

0 (0%)

0 (0%)

  1. Abbreviations: LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, NSCLC non-small cell lung cancer, N number, NOS not otherwise specified